While it is true that CDCA is not the most potent natural TGR5 agonist, the fact that FXR specific agonism has been shown to be harmful in an obesity setting explains this apparent limitation and justifies its use to, once and for all, try to explain these effects. The gene discussed is GPBAR1; the disease is obesity disorder.